Research Article

Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma

Table 2

Clinicopathological features of MBC and NSIBC.

CategoryNSIBC (n = 433)MBC (n = 34a)X2 value

Immunohistochemistry
 ER positive324.00 (74.83%)3.00 (8.82%)65.4242≤0.001
 PR positive301.00 (69.52%)2.00 (5.88%)56.0218≤0.001
 Ki-67 positive372.00 (85.91%)28.00 (82.35%)1.000
 Her-2 positive117.00 (27.02%)5b (15.15%)2.23520.135

Molecular subtypingc
 Luminal A54.00 (12.47%)0.00 (0.00%)8.242≤0.001
 Luminal B282.00 (65.13%)4.00 (11.76%)
 Her-2 positive43.00 (9.93%)3.00 (8.82%)
 Triple-negative54.00 (12.47%)27.00 (79.41%)

a. Among 37 cases of MBC, 34 cases had complete medical history materials. b. In 37 cases of MBC, 33 cases could obtain the level of Her-2, and 34 cases could obtain the expression levels of ER, PR, and Ki-67. c. According to the guidelines of the Chinese Society of Clinical Oncology in 2020, the minimum positive threshold of ER, PR, and Ki-67 were 1%, 1%, and 14%, respectively, and Her-2 (3+) or ISH positivity meant Her-2 positivity. Breast cancer was divided into luminal A (ER/PR positive, Her-2 negative with low Ki-67 index) disease, luminal B (ER/PR positive, Her-2 negative with high Ki-67 index, or ER/PR positive and Her-2 positive) disease, Her-2 positive (ER and PR negative and Her-2 positive) disease, and triple-negative (ER, PR, and Her-2 negative) disease according to molecular subtyping. MBC: metaplastic breast carcinoma; NSIBC: nonspecific invasive breast carcinoma; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2.